ABBV-668 IR / AbbVie - LARVOL DELTA

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Sep 2025 ➔ Dec 2024 | Trial primary completion date: Sep 2025 ➔ Dec 2024

Adverse events • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | Trial completion date: May 2026 ➔ Sep 2025 | Trial primary completion date: May 2026 ➔ Sep 2025

Adverse events • Enrollment closed • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants (clinicaltrials.gov) - P1 | N=25 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: AbbVie | Trial primary completion date: May 2025 ➔ May 2026

Adverse events • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: AbbVie | Trial completion date: Aug 2025 ➔ May 2026

Adverse events • Trial completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

ABBV-668: Data from P2 trial (NCT05570006) for moderate to severe ulcerative colitis in 2025 (AbbVie) - Q4 2023 Results

P2 data • Inflammatory Bowel Disease • Ulcerative Colitis

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2022 ➔ Mar 2023

Adverse events • Enrollment open • Trial initiation date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis